The Dual-Phase Hydrogel is an injectable biomaterial that gels at body temperature, preventing post-operative adhesions and enabling accelerated cell growth to facilitate faster recovery. Its unique gel formation extends the therapeutic effects of wound-healing factors for up to 30 days, significantly outperforming traditional hydrogels that are quickly broken down by the body.

The temperature-sensitive feature allows the Dual-Phase Hydrogel to work as a drug delivery system for accelerating wound healing. The biomaterial turns into a colloid within a minute of injection, and its high viscosity makes it suitable to treat wounds longer, preventing post-surgical adhesions and severe pain. The product biodegrades into water or urine over time.

Dual-Phase Hydrogel, when in a liquid state, can be easily administered by injection, minimizing the risk and complications incurred by surgical interventions. It can be applied to hard-to-reach injury sites such as joints and spine. When in its gelatinous state, the Dual-Phase Hydrogel maintains long-term therapeutic effects since it can occupy the wounded area longer than traditional hydrogels. Depending on the disease, its degradation rate is adjustable, with effects lasting up to 30 days. Currently, no spinal anti-adhesion products have received US FDA approval; however, the Dual-Phase Hydrogel, with an FDA Master File for Devices (MAF), now offers an effective and safe treatment for patients after spinal surgery.

The Dual-Phase Hydrogel provides a revolutionary solution for healing, significantly relieving the pain of patients suffering from diseases such as lumbar laminectomy, knee osteoarthritis, and bone fracture. Its longer residence at the injury site (up to a month) can enhance wound care and avoid repeated injections. It also eliminates the need for open surgery and its risks. With further development of this product, significant medical costs can be saved for both patients and hospitals. Meanwhile, individuals' wellness is greatly improved by this minimally invasive innovation. In collaboration with the University of Georgia, ITRI has successfully introduced Dual-Phase Hydrogel to the US market to treat bone fractures in dogs and cats.